Cyfuse Biomedical (4892) Q2 FY2026 Earnings Analysis: Expanding Business Foundations and the Structural Growth Story in Regenerative Medicine and Devices

The Q2 FY2026 earnings for Cyfuse Biomedical K.K. (Securities Code: 4892), a regenerative medicine venture centered on bio-3D printing technology, have been disclosed. This report provides a multi-faceted analysis and detailed commentary based on the company's earnings presentation materials, covering the latest performance trends, the company's current position in its growth strategy, and specific progress across its three core pillars: "Regenerative Medicine," "Drug Discovery Support," and "Devices."

---

1. External Environment and Overall Financial Performance: Balancing Revenue Growth with Strategic Investment

In line with the Japanese government's "Basic Policies for Economic and Fiscal Management and Reform" (Honebuto no Hoshin), state support for growth investment and the creation of new industries continues to be prioritized. The business sector in which Cyfuse operates is classified under key investment areas such as "Synthetic Biology/Bio" and "Drug Discovery/Advanced Medicine" among the government's 17 strategic growth sectors, positioning the company in an environment where market expansion is expected due to policy tailwinds.

Financial results for the second quarter (interim) of the fiscal year ending December 2026 are as follows:

• Net Sales : 104,321 thousand yen (vs. 29,420 thousand yen in the same period last year, +254.6% YoY)
• Operating Loss : △417,507 thousand yen (vs. △471,248 thousand yen in the same period last year, an improvement of 53,741 thousand yen )
• Net Loss : △434,588 thousand yen (vs. △402,521 thousand yen in the same period last year, a change of △32,067 thousand yen)

Net sales have grown significantly compared to the same period last year, driven by the launch of new products in the device segment and expanded sales in the drug discovery support segment. While the company recorded an operating loss due to SG&A expenses (482,307 thousand yen), primarily driven by R&D, the figures show an improving trend compared to the previous year.

The slide above summarizes the company's current position and financial status within its mid-to-long-term growth phase. Cyfuse defines its current stage as a "Growth Phase" (the period prior to full-scale revenue generation from the market launch of regenerative medicine products). The company is building a structure that steadily accumulates base revenue through the sale of bio-3D printers and contract services for 3D cell products, while simultaneously investing in development and manufacturing for future product launches.

Regarding the balance sheet (B/S), the company maintains a robust cash position with 3,391,527 thousand yen in cash and deposits , and net assets of 2,622,181 thousand yen (equity ratio of 66.8%). This solid financial foundation serves as the bedrock for the long-term clinical development and commercialization preparations of its regenerative medicine products.

---

2. The Three-Pillar Business Portfolio Strategy

Rather than relying on a single drug discovery pipeline, Cyfuse has constructed a unique, autonomous revenue model that integrates the following three areas :

1. Regenerative Medicine : Development and sales of innovative regenerative medicine products ("Growth Revenue" aimed at explosive mid-to-long-term growth).
2. Drug Discovery Support : Development and contract services for 3D cell products (FCD®) and mini-organs/disease models (sustainable "Base Revenue").
3. Devices : Sales and maintenance of bio-3D printers and peripheral culture equipment (the "Foundation" of revenue).

While aiming for exponential revenue growth through the future launch of regenerative medicine products, the company is strengthening its drug discovery support and device segments to serve as short-to-medium-term revenue sources, thereby mitigating the volatility typical of bio-ventures.

---

3. Specific Topics and Progress Analysis by Segment

【Regenerative Medicine】 Clinical Development and Organizational Structure for Multiple Pipelines

In the regenerative medicine segment, significant progress is being made in the primary pipelines of "Peripheral Nerve Regeneration" and "Osteochondral Regeneration."

This slide clearly illustrates the company's dual development strategy for autologous and allogeneic cell products.

• Peripheral Nerve Regeneration (Autologous) : Following positive results from physician-led clinical trials, the company is advancing preparations for corporate-led clinical trials. In collaboration with partners Kyoto University, Taiyo Holdings, and Taiyo Pharma Tech, it is strengthening the industry-academia-government framework to obtain manufacturing approval.
• Peripheral Nerve Regeneration (Allogeneic) : As part of an AMED project, a physician-led clinical trial for allogeneic peripheral nerve regeneration is currently underway as of Q2 2026. By utilizing allogeneic cells, the company is advancing toward a second-generation product that offers reduced manufacturing costs and immediate availability.
• Osteochondral Regeneration : The company is steadily advancing toward clinical trials for conditions such as osteoarthritis, having completed manufacturing pre-runs, ethics committee applications/approvals, and the submission of clinical trial notifications in Q2 2026. In collaboration with Keio University and Fujita Health University, the construction of clinical and manufacturing systems is entering the final stage.

Furthermore, the company has entered into a capital and business alliance with Kuraray Co., Ltd. to facilitate future social implementation and commercialization. It is also advancing mass-culture technology development with ZACROS Corporation and Chiyoda Corporation, accelerating the construction of a commercial production network.

【Drug Discovery Support】 New Product Sales and Market Development

In the drug discovery support segment, the company has commenced sales and contract services for its new product, the "Human 3D Mini-Liver®/Disease Model." In addition to establishing partnerships with five domestic distributors, the company is targeting markets beyond the traditional pharmaceutical industry, such as the food sector (functional food development), by exhibiting at trade shows like "ifia JAPAN" and "FOOMA JAPAN."

Furthermore, the company demonstrated its technological superiority at international conferences such as the "2026 MPS World Summit" held in the U.S., aiming to increase its recognition in the global market.

【Devices】 Deployment of Next-Generation Machines for Commercial Production

In the device segment, development is progressing not only on bio-3D printer sales but also on products aimed at automating and standardizing cell processing workflows.

As introduced in the slide above, the company is evolving its devices toward clinical and commercial production models.

• New Product "CAP" (Compact Automated Pipetting system) : Sales commenced in June 2026, addressing the need for improved operational efficiency in research and manufacturing environments.
• Development of Circulation Culture Pumps : Development has been completed for a circulation culture pump that can be used inside incubators during the maturation culture process.
• Collaboration with NSK (NSK Ltd.) : The company is developing a new type of bio-3D printer for the commercial production of regenerative medicine and 3D cell products, with technical presentations already delivered at events such as the Japanese Society for Regenerative Medicine.

---

4. Summary and Future Outlook

Cyfuse's Q2 FY2026 earnings show a significant expansion in net sales to 104,321 thousand yen, approximately 3.5 times that of the same period last year, demonstrating the steady growth of its business foundation.

The key points in the company's future growth story can be summarized as follows:

1. Acceleration of Clinical Development : Enhancement of pipeline value through the progress of physician-led clinical trials for allogeneic peripheral nerve regeneration and the completion of clinical trial notifications for osteochondral regeneration.
2. Establishment of Large-Scale Manufacturing and Partnerships : Realization of a commercial production system (mass production and automation) through collaborations with major players such as Kuraray, ZACROS, Chiyoda, and NSK.
3. Expansion of Base Revenue : Strengthening cash flow generation in the drug discovery support and device segments through the introduction of new products like "CAP" and "Human 3D Mini-Liver®."

Backed by a strong balance sheet (approx. 3.39 billion yen in cash and deposits), these earnings confirm that the company is steadily transitioning from R&D to commercial production and market launch.